Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug ...

This week, the FDA granted priority review status to J&J’s JNJ application seeking approval of key pipeline candidate ...

Shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) fell 2.4% in pre-open trading Friday as the company announced a strategic reorganization focusing on key valu ...

Diamyd Medical provides an update following the receipt of final meeting minutes from a positive Type C meeting with the U.S. Food and Drug Administration ...

Conference call to discuss positive initial Phase 1 clinical data today at 8:30 a.m. ETCAMBRIDGE, Mass., Jan. 10, 2025 (GLOBE ...

In 2024, Zymeworks made significant progress, including initiating first-in-human global studies for various therapeutic ...

Our fair value estimate for WuXi is HKD 24.60 per share. WuXi has been growing at a CAGR of 53.3% for the past eight years. Although its USD 20.5 billion total backlog revenue supports our growth ...

Roche has licensed an antibody-drug conjugate (ADC) designed to treat advanced small-cell lung cancer from China-based Innovent Biologics for $80 million up front and up to $1 billion in milestone ...

Intellia said the Phase 3 HAELO study evaluating NTLA-2002 for HAE to complete enrollment in the second half of 2025, and the company plans to ...

The application is supported by data from the randomized, double-blind, placebo-controlled phase 3 Vivacity-MG3 study.

Johnson & Johnson pauses U.S. Varipulse cases to investigate neurovascular events. The FDA-approved device integrates PFA ...

A clinical-stage biotechnology company will advance a novel autologous chimeric antigen receptor T-cell therapy that targets ...